[CSF levels of amikacin following systemic application in patients with slightly and severely impaired blood cerebrospinal barrier (author's transl)].
Levels of amikacin after systemic application of 350 mg were determined by the agar well diffusion method in 12 samples of CSF and serum of 7 patients with bacterial meningitis and in 2 samples of 2 patients with viral meningitis. Only in 2 samples of CSF drawn after the first systemic application of 350 mg i.m. no antibiotic activity was detectable. In 7 specimens of CSF levels of amikacin were greater than or equal to 3 microgram/ml. In 12 tests of CSF of neurosurgical patients with only slight impairment of the blood-CSF-barrier, taken for comparison reasons, only in 6 samples antibiotic activity was found. Only one test revealed CSF-concentration of amikacin higher then 3 microgram/ml.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000134:cerebrospinal fluid* / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008581:Meningitis / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D008587:Meningitis, Viral / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D008875:Middle Aged
D007612:Kanamycin; D000583:Amikacin
Liquorkonzentrationen von amikacin nach systemischer gabe bei patienten mit gering und stark gestörter blut-liquor-schranke.